Radiopharm Theranostics RADX
NASDAQ RADX
$2.15 +0.09 (+4.36%)
As of: Sep 10, 2026 · 10:29 AM EDT

Radiopharm Theranostics Ltd (RADX) Non Operating Interest Expenses (2023 - 2025)

Radiopharm Theranostics' (RADX) quarterly Non Operating Interest Expenses came in at -$65300.0 in Q2 2025, up 89.84% year-over-year from -$34396.9 in Q2 2024, and up 89.84% quarter-over-quarter from -$642888.0 in Q2 2024.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Radiopharm Theranostics Ltd (RADX) Non Operating Interest Expenses (2023 - 2025) Analysis & Trends

Radiopharm Theranostics (RADX) has reported Non Operating Interest Expenses for 3 consecutive years, with -$65300.0 the latest figure, recorded in Q2 2025.

Peer Set

Peer Comparison

All peers
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -65,300.00
Jun 30, 2024 -642,888.00
Jun 30, 2023 -86,091.00